Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 47Carcinoma, Non-Small-Cell Lung 14Neoplasm Metastasis 11Neoplasms 9Colorectal Neoplasms 8Breast Neoplasms 8Triple Negative Breast Neoplasms 7Lung Neoplasms 6Sarcoma 5Melanoma 4Esophageal Neoplasms 3Cholangiocarcinoma 3Brain Neoplasms 3Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Pancreatic Diseases 2Gastrointestinal Neoplasms 2Carcinoma 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Tongue Neoplasms 1TNBC 1Solid Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1

Interventions

Carboplatin 16Paclitaxel 9Cyclophosphamide 8liposomal doxorubicin 6Peripheral Blood Stem Cell Transplantation 6Topotecan 5Filgrastim 5pembrolizumab 4Docetaxel 4oregovomab 3veliparib 2sacituzumab govitecan 2epacadostat 2avelumab 2Thiotepa 2Taxes 2STA 9090 2Nivolumab 2Erlotinib Hydrochloride 2Drug Therapy 2Cisplatin 2Amifostine 2talazoparib 1ribociclib 1relacorilant 1ralimetinib 1poly ICLC 1phenoxodiol 1peginterferon alfa-2b 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Ovarian Epithelial × 130-nm albumin-bound paclitaxel × Clear all
NCT02762981 2022-12-06

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Corcept Therapeutics

Phase 1/2 Completed
85 enrolled 24 charts
BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡